*A randomized controlled study of the efficacy of an intensified, partial inpatient adaptation of Dialectical Behavior Therapy (DBT) for a population of Borderline patients (young adults/adults:18 - 40), compared with standard outpatient DBT*

Completed

• Conditions: severe emotional disturbance; severe personality disorder; suicidal/ selfdestructive behavior; 10034726

• Registration Number: NL-OMON35751
• Lead Sponsor: Stichting Rivierduinen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 72

Inclusion Criteria

(young) adult borderline patients with severe suicidal and selfdestructive behavior with al least 6 out of 9 diagnostic criteria of the DSM-IV TR of the bordeline personality disorder, with a Borderline Personality Disorder Severity Index total score of at least 24.

Exclusion Criteria

IQ < 80, a chronic psychotic condition, bipolar disorder, hard drug abuse and a forced treatment framework.

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p> Main study parameter is the number of suicide attempts/self-destructive acts<br /><br>(measured by the Life Time Parasuicide Count and The Borderline Personality<br /><br>Severity Index). We expect that after 12 weeks 20% of the patients of the<br /><br>intervention group still show suicidal and/or self-destructive behaviour<br /><br>compared to 60% of the patients in the control condition, and that this<br /><br>difference sustains at 24 weeks and will gradually be reduced between 24 and 52<br /><br>weeks. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Second study parameter is the severity of borderline symptomatology (as<br /><br>measured by the BPDSI), reduced BPDSI scores. The results on the SF-36 (Quality<br /><br>of life), on the BSI (psychopathological symptoms) and on the IDS-SR<br /><br>(depression), part of the Routine Outcome Monitoring of Rivierduinen, will be<br /><br>taken into account also. We expect a stronger decline in LPC scores and in<br /><br>BPDSI general symptomatology scores in the first 4 months, and that these<br /><br>differences sustain at 24 weeks and will gradually be reduced between 24 and 52<br /><br>weeks. </p><br>